Information Provided By:
Fly News Breaks for November 22, 2019
Nov 22, 2019 | 11:11 EDT
Canaccord Genuity analyst Arlinda Lee raised her price target for Harpoon Therapeutics (HARP) to $26 from $22 after the company and AbbVie (ABBV) expanded their existing collaboration and entered into a new agreement. The analyst views the agreement as further external validation of Harpoon's TriTAC platform, and she notes the company's $100M in near-term cash extends its runway well into the second half of 2022. Lee reiterates a Buy rating on Harpoon Therapeutics.
News For ABBV;HARP From the Last 2 Days
Dec 6, 2021 | 09:40 EST
Unusual total active option classes on open include: WeWork (WE), SPDR S&P Regional Banking (KRE), Ardelyx (ARDX), DocuSign (DOCU), Pinduoduo (PDD), Rocket Lab USA (RKLB), Global X Uranium (URA), Norwegian Cruise Line (NCLH), Chewy (CHWY), and AbbVie (ABBV).
Dec 6, 2021 | 08:32 EST
AbbVie announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week 12. The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60% having previously failed two or more biologics. U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. "The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino, M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."